Defence Therapeutics Inc. (DTCFF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Defence Therapeutics Inc. (DTCFF) trades at $0.3444 with AI Score 42/100 (Grade C). Defence Therapeutics Inc. is a biotechnology company focused on developing biological and biosimilar therapeutic drugs for cancer and infectious diseases. Market cap: $26.1M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for DTCFF: DTCFF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DTCFF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DTCFF: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Defence Therapeutics Inc. (DTCFF) Healthcare & Pipeline Overview
Defence Therapeutics Inc., a biotechnology firm, pioneers precision medicine through its ACCUMTM platform, enabling targeted delivery of immunotherapies and antibody-drug conjugates. Focusing on cancer and infectious diseases, Defence Therapeutics aims to enhance treatment efficacy and reduce side effects, positioning itself within the rapidly evolving biopharmaceutical landscape with a market capitalization of $26.1M.
What Is the Investment Thesis for DTCFF?
Defence Therapeutics Inc. presents a notable research candidate within the biotechnology sector, driven by its innovative ACCUMTM technology and diversified product pipeline targeting cancer and infectious diseases. The company's focus on precision delivery of immunotherapies and ADCs addresses a critical need for more effective and less toxic treatments. Key value drivers include the successful advancement of its dendritic cell cancer vaccines and ADC products through clinical trials, as well as potential partnerships with larger pharmaceutical companies. The company's market capitalization of $26.1M suggests significant upside potential if clinical milestones are achieved. Ongoing catalysts include the continued development of its COVID-19 vaccine formulation and expansion of its ADC pipeline. Potential risks include the inherent uncertainties of drug development, regulatory hurdles, and the need for additional funding to support ongoing research and clinical trials. The company's negative P/E ratio of -7.41 reflects its current stage of development and lack of profitability.
Based on FMP financials and quantitative analysis
DTCFF Key Highlights
Proprietary ACCUMTM technology enables precision delivery of vaccine antigens and ADCs, potentially enhancing therapeutic efficacy.
- Focus on developing dendritic cell cancer vaccines, addressing a significant unmet need in oncology.
- Development of protein-based vaccine formulation against COVID-19 and other infectious diseases, positioning the company in a high-growth market.
- Market capitalization of $26.1M, indicating potential for significant growth if clinical milestones are achieved.
- Beta of 1.39 suggests higher volatility compared to the overall market.
Who Are DTCFF's Competitors?
DTCFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BBIXF Bonus BioGroup Ltd. | $0.08 | +0.00% | $93.4M | 48 |
| CLYYF Celyad Oncology S.A. | $0.28 | +0.00% | $12.5M | 61 |
| FNCH Finch Therapeutics Group, Inc. | $10.20 | +0.99% | $16.4M | — |
| MBXBF Microbix Biosystems Inc. | $0.22 | -4.82% | $29.8M | 46 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DTCFF's Key Strengths?
Proprietary ACCUMTM technology for targeted drug delivery
- Focus on developing novel therapies for cancer and infectious diseases
- Experienced management team with expertise in biotechnology
- Strong intellectual property portfolio
What Are DTCFF's Weaknesses?
Limited financial resources compared to larger pharmaceutical companies
- Early stage of development with no products currently on the market
- Dependence on successful clinical trial outcomes
- High risk of failure inherent in drug development
What Could Drive DTCFF Stock Higher?
Advancement of dendritic cell cancer vaccines through clinical trials.
- Development of protein-based vaccine formulation against infectious diseases.
- Expansion of antibody-drug conjugate (ADC) pipeline targeting various cancers.
- Pursuit of strategic partnerships with pharmaceutical companies.
- Geographic expansion into new markets.
What Are the Key Risks for DTCFF?
Financial-distress signal — its Altman Z-Score of -0.34 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Unsuccessful clinical trial outcomes for its therapeutic candidates.
- Regulatory hurdles and lengthy approval processes for new drugs.
- Competition from larger pharmaceutical companies with greater resources.
- Dependence on securing additional funding to support research and development.
- Limited liquidity and price volatility due to trading on the OTC market.
What Are the Growth Opportunities for DTCFF?
- Expansion of Dendritic Cell Cancer Vaccine Pipeline: Defence Therapeutics has the opportunity to expand its dendritic cell cancer vaccine pipeline to target a broader range of cancer types. The global cancer vaccine market is projected to reach $7.9 billion by 2027, driven by the increasing prevalence of cancer and the growing demand for personalized immunotherapies. By leveraging its ACCUMTM technology, Defence Therapeutics can develop novel vaccines that enhance the immune response against cancer cells, potentially leading to improved patient outcomes. Timeline: Ongoing research and preclinical studies, with potential clinical trials within the next 2-3 years.
- Advancement of Antibody-Drug Conjugate (ADC) Products: Defence Therapeutics can capitalize on the growing ADC market by advancing its ADC products targeting various cancers. The global ADC market is projected to reach $29.4 billion by 2030, driven by the increasing success of ADCs in treating hematological malignancies and solid tumors. Defence Therapeutics' ACCUMTM technology can enhance the delivery of cytotoxic payloads to cancer cells, potentially improving the efficacy and reducing the toxicity of ADCs. Timeline: Ongoing preclinical studies, with potential clinical trials within the next 3-4 years.
- Development of Protein-Based Vaccine Formulation Against Infectious Diseases: Defence Therapeutics has the opportunity to develop a protein-based vaccine formulation against COVID-19 and other infectious diseases. The global vaccine market is projected to reach $62.1 billion by 2027, driven by the ongoing COVID-19 pandemic and the increasing awareness of the importance of vaccination. Defence Therapeutics' vaccine formulation can provide a safe and effective means of preventing infectious diseases, particularly in vulnerable populations. Timeline: Ongoing research and preclinical studies, with potential clinical trials within the next 1-2 years.
- Strategic Partnerships with Pharmaceutical Companies: Defence Therapeutics can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its products. These partnerships can provide access to funding, expertise, and distribution channels, enabling Defence Therapeutics to reach a wider market and maximize the value of its assets. The pharmaceutical industry is increasingly seeking innovative technologies and products to enhance their pipelines, creating opportunities for collaboration with biotechnology companies like Defence Therapeutics. Timeline: Ongoing discussions with potential partners, with potential agreements within the next 1-2 years.
- Geographic Expansion into New Markets: Defence Therapeutics can expand its geographic presence into new markets, such as Europe and Asia, to capitalize on the growing demand for innovative therapies. These markets offer significant growth potential, driven by increasing healthcare spending and the rising prevalence of cancer and infectious diseases. By establishing a presence in these markets, Defence Therapeutics can access new customer segments and diversify its revenue streams. Timeline: Ongoing market research and planning, with potential expansion within the next 2-3 years.
What Are DTCFF's Competitive Advantages?
- Proprietary ACCUMTM technology platform provides a unique advantage in targeted drug delivery.
- Strong intellectual property portfolio protects its innovative technologies.
- Focus on developing novel therapies for unmet medical needs.
- Experienced management team with expertise in biotechnology and drug development.
- Strategic partnerships with leading research institutions and pharmaceutical companies.
What Does DTCFF Do?
Defence Therapeutics Inc., established in 2017 and headquartered in Vancouver, Canada, is a biotechnology company dedicated to the research and development of innovative biological and biosimilar therapeutic drugs. The company's core focus lies in addressing critical unmet needs in cancer treatment and infectious disease management. Defence Therapeutics operates with a proprietary platform known as ACCUMTM, a technology designed to enhance the precision delivery of vaccine antigens and antibody-drug conjugates (ADCs) directly to target cells. This technology facilitates the delivery of these agents in their intact form, potentially improving therapeutic efficacy and reducing systemic toxicity. Defence Therapeutics' product pipeline includes the development of dendritic cell cancer vaccines, protein-based vaccine formulations against COVID-19 and other infectious diseases, and ADC products targeting a spectrum of cancers. The company’s ACCUMTM technology is designed to improve the intracellular delivery of antigens and therapeutic molecules, thereby enhancing the immune response and treatment outcomes. The company was initially incorporated as Accum Therapeutics Inc. and rebranded as Defence Therapeutics Inc. in March 2020, marking a strategic shift towards its current focus on immune-oncology and infectious diseases. Defence Therapeutics is committed to advancing its research programs through preclinical and clinical studies, with the goal of bringing novel therapies to market that can significantly improve patient outcomes.
What Products and Services Does DTCFF Offer?
- Researches and develops biological therapeutic drugs.
- Creates biosimilar therapeutic drugs.
- Focuses on treatments for cancer.
- Develops treatments for infectious diseases.
- Utilizes the ACCUMTM technology for targeted drug delivery.
- Develops dendritic cell cancer vaccines.
- Formulates protein-based vaccines against COVID and other infectious diseases.
- Creates antibody drug conjugates (ADCs) targeting various cancers.
How Does DTCFF Make Money?
- Develops and patents novel therapeutic technologies.
- Conducts preclinical and clinical trials to validate efficacy and safety.
- Seeks partnerships with pharmaceutical companies for commercialization.
- Out-licenses its technologies to other companies.
- Generates revenue through licensing fees, milestone payments, and royalties.
What Industry Does DTCFF Operate In?
Defence Therapeutics operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation, high R&D spending, and stringent regulatory requirements. Defence Therapeutics' focus on precision delivery of immunotherapies and ADCs aligns with the industry trend towards targeted therapies and personalized treatment approaches. Competitors include companies such as BBIXF (BioBoron Innovations Inc.) and CLYYF (Calyxt Inc.), each with their own proprietary technologies and therapeutic focuses. Defence Therapeutics differentiates itself through its ACCUMTM platform, which aims to improve the intracellular delivery of antigens and therapeutic molecules.
Who Are DTCFF's Key Customers?
- Pharmaceutical companies seeking innovative drug delivery technologies.
- Hospitals and cancer centers using dendritic cell cancer vaccines.
- Patients with cancer and infectious diseases.
- Research institutions conducting studies on immunotherapies.
- Government agencies involved in public health initiatives.
Financial Health
Defence Therapeutics Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.34 places it in the distress zone, a signal of elevated financial risk.
DTCFF Valuation & Market Position
With a $26.1M market cap, Defence Therapeutics Inc. sits in the micro-cap segment of the market. Relative to its peer group, DTCFF's quantitative score of 42/100 is below the peer average of 59/100.
Key Financial Metrics
Return on assets is -67.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -14.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.4%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Defence Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Sébastien Plouffe. DTCFF has traded publicly since 2021.
DTCFF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary ACCUMTM technology for targeted drug delivery
- Focus on developing novel therapies for cancer and infectious diseases
- Experienced management team with expertise in biotechnology
- Strong intellectual property portfolio
Bear Case
- Limited financial resources compared to larger pharmaceutical companies
- Early stage of development with no products currently on the market
- Dependence on successful clinical trial outcomes
- High risk of failure inherent in drug development
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
DTCFF Latest News
No recent news available for DTCFF.
DTCFF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DTCFF.
Price Targets
Wall Street price target analysis for DTCFF.
DTCFF MoonshotScore
What does this score mean?
The MoonshotScore rates DTCFF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Sebastien Plouffe
CEO
Sebastien Plouffe is the CEO of Defence Therapeutics Inc. His background likely includes experience in the biotechnology or pharmaceutical industry, with a focus on drug development, business strategy, and corporate leadership. Further details regarding his specific educational background and previous roles are not available in the provided data. However, his position as CEO suggests a strong understanding of the biotechnology landscape and the challenges and opportunities facing companies in this sector.
Track Record: As CEO of Defence Therapeutics Inc., Sebastien Plouffe has been responsible for guiding the company's strategic direction and overseeing the development of its ACCUMTM technology and product pipeline. Key milestones under his leadership likely include the rebranding of the company from Accum Therapeutics Inc. to Defence Therapeutics Inc. in March 2020, as well as the advancement of its dendritic cell cancer vaccines, protein-based vaccine formulations, and ADC products through preclinical and clinical studies. Specific achievements and financial metrics are not available in the provided data.
DTCFF OTC Market Information
The OTC Other tier, where Defence Therapeutics Inc. (DTCFF) trades, represents the lowest tier of the OTC market. Companies in this tier often face challenges in meeting minimum financial standards required for listing on major exchanges like NYSE or NASDAQ. These companies may be early-stage ventures, distressed entities, or those choosing to remain private but still seeking to provide some liquidity for their shareholders. Investing in OTC Other stocks carries significantly higher risk due to limited regulatory oversight and disclosure requirements compared to listed companies.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements on the OTC market.
- Potential for illiquidity and price volatility due to low trading volume.
- Increased risk of fraud and manipulation compared to listed exchanges.
- Difficulty in obtaining reliable and up-to-date financial information.
- Higher likelihood of delisting or going out of business.
- Verify the company's registration and legal status.
- Obtain and review the company's financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and technology.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- The company has a clear business plan and strategy.
- The company has a management team with relevant experience.
- The company has a proprietary technology or product.
- The company has secured patents or other intellectual property protection.
- The company has a website and provides some information about its operations.
What Investors Ask About Defence Therapeutics Inc. (DTCFF) — Healthcare
What does the AI Score mean for DTCFF?
DTCFF holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Defence Therapeutics Inc. is a biotechnology company focused on developing biological and biosimilar therapeutic drugs for cancer and infectious diseases. Their proprietary ACCUMTM technology …
What does Defence Therapeutics Inc. do?
Defence Therapeutics Inc. is a biotechnology company focused on the research and development of biological and biosimilar therapeutic drugs for cancer and infectious diseases. The company's core technology is the ACCUMTM platform, which enhances the delivery of vaccine antigens and antibody-drug conjugates (ADCs) to target cells.
What are the main risks for DTCFF?
The main risks for Defence Therapeutics Inc. include the inherent uncertainties of drug development, such as the potential for unsuccessful clinical trial outcomes and regulatory hurdles. The company also faces competition from larger pharmaceutical companies with greater resources. Additionally, Defence Therapeutics is dependent on securing additional funding to support its research and development activities.
What are the key factors to evaluate for DTCFF?
Defence Therapeutics Inc. (DTCFF) holds an AI score of 42/100 (low). presents a notable research candidate within the biotechnology sector, driven by its innovative ACCUMTM technology and diversified product pipeline targeting cancer and infectious diseases. Not financial advice.
How frequently does DTCFF data refresh on this page?
DTCFF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven DTCFF's recent stock price performance?
Defence Therapeutics Inc. (DTCFF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary ACCUMTM technology for targeted drug delivery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DTCFF overvalued or undervalued right now?
Defence Therapeutics Inc. (DTCFF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research DTCFF before investing?
Before investing in Defence Therapeutics Inc. (DTCFF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding DTCFF to a portfolio?
Key strength of Defence Therapeutics Inc. (DTCFF): Proprietary ACCUMTM technology for targeted drug delivery. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for Defence Therapeutics Inc.
- AI analysis pending, resulting in incomplete information.
- OTC market investments carry higher risk.